
CLAIMS

1. A compound suitable for the preparation of an agent for use in imaging and/or radiotherapy, the compound having Formula I:



(I)

wherein:

Z^1 is attached to the N-terminus of cMBP, and is Q;

Z^2 is attached to the C-terminus of cMBP, and is Q;

cMBP is a cMet binding cyclic peptide of 17 to 30 amino acids, which comprises the amino acid sequence (SEQ-7):

Ala-Gly-Ser-Cys^a-Tyr-Cys^c-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys^d-Trp-Cys^b-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys;

wherein: Cys^{a-d} are each cysteine residues such that residues a and b as well as c and d are cyclised to form two separate disulphide bonds;

each occurrence of Q is independently at least one of:

a metabolism inhibiting group (M^{IG}), which is a biocompatible group that inhibits or suppresses *in vivo* metabolism of the peptide, wherein for the N-terminus (Z^1) M^{IG} is -NH(C=O)R^G, where R^G is chosen from C_{1-6} alkyl, C_{3-10} aryl groups or comprises a polyethyleneglycol (PEG) building block; and for the C-terminus (Z^2)

M^{IG} is chosen from carboxamide, tert-butyl ester, benzyl ester, cyclohexyl ester, amino alcohol or a polyethyleneglycol (PEG) building block,

a tumour retention group (T^{RG}), which is a biocompatible group that enhances retention in tumour cells or the like *in vivo*, wherein T^{RG} is chosen from polyamines, polylysines, PEG (monodisperse), albumin, fatty linear carbon chains or sugars (glycosylation), and

a biodistribution enhancement group (D^{EG}), which is a biocompatible group that enhances biodistribution and/or prolongs blood retention *in vivo*,
wherein D^{EG} is chosen from polyamines, polylysines, PEG (monodisperse), albumin, fatty linear carbon chains or sugars (glycosylation); and

IM is a chelating agent suitable for complexing a radioactive moiety, wherein the chelating agent is at least one of: DOTAGA (2,2′,2”-(10-(1,4-dicarboxy-ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid), and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid).

2. The compound of claim 1, wherein the radioactive moiety is at least one of an alpha ray (α) emitter, a beta ray (β) emitter and a gamma ray (γ) emitter.

3. The compound of claim 2, wherein the beta ray emitter is at least one of an electron (β^-) emitter and a positron (β^+) emitter.

4. The compound of any preceding claim, wherein the compound is for use in one or more of positron-emission tomography (PET), single-photon emission computed tomography (SPECT),

scintigraphy and radiotherapy, optionally wherein the compound is for use in radiotherapy.

5. The compound of any preceding claim, wherein the radioactive moiety is selected from one or more of the group consisting of: ^{90}Y, ^{177}Lu, ^{188}Re, ^{186}Re, ^{67}Cu, ^{212}Bi, ^{213}Bi, ^{211}At, ^{225}Ac, ^{131}I, ^{166}Ho, ^{149}Pm, ^{199}Au, ^{105}Rh, ^{227}Th, ^{153}Sm, ^{89}Sr, ^{223}Ra, ^{77}Br, ^{123}I, ^{125}I, ^{99m}Tc, ^{67}Ga, ^{111}In, ^{68}Ga, ^{64}Cu, ^{89}Zr, ^{11}C, ^{15}O, ^{13}N, ^{82}Rb and ^{18}F, and suitable salts thereof.

6. The compound of any preceding claim, wherein the radioactive moiety is selected from one or more of the group consisting of: ^{68}Ga, ^{18}F, ^{89}Zr, ^{177}Lu, ^{225}Ac, ^{213}Bi, ^{227}Th and ^{90}Y, and suitable salts thereof.

7. The compound of any preceding claim, wherein the radioactive moiety is ^{177}Lu, or suitable salts thereof.

8. The compound of any preceding claim, wherein Q is M^{IG}.

9. The compound of any preceding claim, wherein Z^1 is acetyl and Z^2 is a primary amine.

10. A pharmaceutical composition comprising the compound of any one of claims 1 to 9 and a biocompatible carrier, in a form suitable for mammalian administration, optionally wherein the pharmaceutical composition further comprises a radioactive moiety.

11. The pharmaceutical composition of claim 10, having a dosage for a single patient and being provided in a suitable syringe or container.

12. A kit for the preparation of the pharmaceutical composition of claim 10 or claim 11, the kit comprising the compound of any one of claims 1 to 9 in sterile, solid form such that upon reconstitution with a sterile supply of the biocompatible carrier of claim 10 or claim 11, dissolution occurs to give the desired pharmaceutical composition, optionally wherein the kit further comprises a radioactive moiety.

13. A method of imaging of the mammalian body comprising use of at least one of the compound of any one of claims 1 to 9 and the pharmaceutical composition of claim 10 or claim 11, wherein the compound comprises the radioactive moiety, and wherein the pharmaceutical composition further comprises the radioactive moiety.

14. The method of claim 13, wherein the imaging is *in vivo*.

15. The method of claim 13 or claim 14, wherein the imaging is at least one of PET imaging, scintigraphy and SPECT imaging, optionally wherein the imaging is SPECT imaging.

16. The method of any one of claims 13 to 15, wherein the imaging is to obtain images of sites of cMet over-expression or localisation *in vivo*.

17. The method of any one of claims 13 to 16, wherein the compound of any one of claims 1 to 9 or the pharmaceutical composition of claim 10 or claim 11 has been previously administered to the mammalian body.

18. The method of any one of claims 13 to 17, wherein the method comprises the steps of:
    a) administering at least one of the compound of any one of claims 1 to 9 and the pharmaceutical composition of claim 10 or claim 11;
    b) detecting emission from the radioactive moiety, which is generated by the decay of the radioactive moiety; and
    c) forming an image of the tissue of interest from the emission of step (b).

19. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical composition further comprises the radioactive moiety, for use as at least one of: an imaging agent in imaging of the mammalian body, and a radiotherapeutic agent in radiotherapy of the mammalian body, optionally for use as a radiotherapeutic agent in radiotherapy of the mammalian body.

20. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical composition further comprises the radioactive moiety, for use as both: an imaging agent in imaging of the mammalian body, and a radiotherapeutic agent in radiotherapy of the mammalian body.

21. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical

composition further comprises the radioactive moiety, for use as a medicament.

22. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical composition further comprises the radioactive moiety, for use in detection, diagnosis, prognosis, prediction of outcome, surgery, staging, treatment, therapy, radiotherapy, monitoring of treatment, monitoring of disease progression and/or monitoring therapy.

23. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical composition further comprises the radioactive moiety, for use in the detection, diagnosis, prognosis, prediction of outcome, surgery, staging, treatment, therapy, radiotherapy, monitoring of treatment, monitoring of disease progression and/or monitoring therapy of cancer.

24. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical composition further comprises the radioactive moiety, for use in the detection, diagnosis, prognosis, prediction of outcome, surgery, staging, treatment, therapy, radiotherapy, monitoring of treatment, monitoring of disease progression and/or monitoring therapy of sites of cMet over-expression or localisation, wherein the use is in imaging, and wherein the imaging is to obtain images of sites of cMet over-expression or localisation.

25. The compound of any one of claims 1 to 9 wherein the compound comprises the radioactive moiety, or the pharmaceutical composition of claim 10 or claim 11 wherein the pharmaceutical composition further comprises the radioactive moiety, for use in obtaining an image of sites of cMet over-expression or localisation *in vivo*.